Clinical Trial Update: Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating adavosertib in combination with irinotecan hydrochloride for relapsed or refractory solid tumors in younger patients; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Embryonal Tumor Not Otherwise Specified
• Central Nervous System Embryonal Tumor with Rhabdoid Features
• Central Nervous System Ganglioneuroblastoma
• Central Nervous System Neoplasm
• Childhood Central Nervous System Embryonal Neoplasm
• Embryonal Tumor with Multilayered Rosettes C19mc-altered
• Malignant Solid Neoplasm
• Medulloblastoma
• Neuroblastoma
• Pineoblastoma
• Rhabdomyosarcoma

Drugs mentioned

• Adavosertib (adavosertib)
• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-10-05